文献速递淋巴瘤

原发性渗出性淋巴瘤的病毒学、免疫学及临床特征

Viral, immunologic, and clinical features of primary effusion lymphoma.
PubMed 文献 · Blood · 2019-02-19

研究纳入2000至2013年诊断的20例原发性渗出性淋巴瘤(PEL)患者,其中19例接受改良EPOCH方案治疗,对比20例HIV相关弥漫大B细胞淋巴瘤和19例KSHV相关多中心Castleman病。PEL患者中位总生存期22个月,3年癌症特异性生存率47%,EBV阳性与生存改善相关(HR 0.27),IL-6升高与生存不良相关(HR 6.1)。

要点

  • PEL与HIV相关弥漫大B细胞淋巴瘤相比,显著低白蛋白血症(P<.0027)、血小板减少(P=.0045)和IL-10升高(P<.0001)。
  • 接受治疗的PEL患者中位总生存期22个月,2年后生存曲线出现平台期,3年癌症特异性生存率47%。
  • EBV阳性肿瘤状态与生存改善相关(HR 0.27,P=.038),IL-6升高与生存不良相关(HR 6.1,P=.024)。

核心结论

  • IL-6和IL-10水平参与PEL的自然病史,炎症细胞因子和肿瘤EBV状态是最强的预后因素。
  • 需要针对发病机制的一线方案来改善PEL的总生存期。

研究设计与样本

  • 研究识别了2000年至2013年间诊断的20例PEL患者,其中19例接受改良输注型依托泊苷、长春新碱、多柔比星联合环磷酰胺和泼尼松(EPOCH)治疗。
  • 将PEL患者的临床、病毒学和免疫学特征与20例HIV相关弥漫大B细胞淋巴瘤患者及19例有症状的白介素-6相关KSHV相关多中心Castleman病患者进行比较。
  • 对接受治疗的PEL患者进行生存分析,以识别预后因素和癌症特异性死亡率。

主要发现

  • 与HIV相关弥漫大B细胞淋巴瘤相比,PEL与显著低白蛋白血症(P<.0027)、血小板减少(P=.0045)和IL-10水平升高(P<.0001)相关。
  • PEL与KSHV相关多中心Castleman病在这些参数上无显著差异。
  • 接受治疗的PEL患者中位总生存期为22个月,2年后生存曲线出现平台期,3年癌症特异性生存率为47%。
  • EBV阳性肿瘤状态与生存改善相关(风险比0.27;P=.038),IL-6水平升高与生存不良相关(风险比6.1;P=.024)。

关键数值与推荐

  • PEL与HIV相关弥漫大B细胞淋巴瘤比较:低白蛋白血症P<.0027,血小板减少P=.0045,IL-10升高P<.0001。
  • 接受治疗的PEL患者中位总生存期22个月,3年癌症特异性生存率47%。
  • EBV阳性肿瘤状态与生存改善相关:风险比0.27,P=.038。
  • IL-6水平升高与生存不良相关:风险比6.1,P=.024。

临床怎么用

  • 作者认为,炎症细胞因子和肿瘤EBV状态是最强的预后因素。
  • 作者建议,需要针对发病机制的一线方案来改善PEL的总生存期。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary effusion lymphoma (PEL) is an aggressive HIV-associated lymphoma with a relatively poor prognosis in the era of effective HIV therapy. Kaposi sarcoma herpesvirus (KSHV) is the etiologic agent, and ∼80% of tumors are coinfected with Epstein-Barr virus (EBV). A better understanding of how KSHV-related immune dysregulation contributes to the natural history of PEL will improve outcomes. Twenty patients with PEL diagnosed between 2000 and 2013, including 19 treated with modified infusional etoposide, vincristine, and doxorubicin with cyclophosphamide and prednisone (EPOCH), were identified. We compared their clinical, virologic, and immunologic features vs 20 patients with HIV-associated diffuse large B-cell lymphoma and 19 patients with symptomatic interleukin (IL)-6 related KSHV-associated multicentric Castleman disease. Survival analyses of treated patients with PEL were then performed to identify prognostic factors and cancer-specific mortality. Compared with HIV-associated diffuse large B-cell lymphoma, PEL was associated with significant hypoalbuminemia (P < .0027), thrombocytopenia (P = .0045), and elevated IL-10 levels (P < .0001). There were no significant differences in these parameters between PEL and KSHV-associated multicentric Castleman disease. Median overall survival in treated patients with PEL was 22 months, with a plateau in survival noted after 2 years. Three-year cancer-specific survival was 47%. EBV-positive tumor status was associated with improved survival (hazard ratio, 0.27; P = .038), and elevated IL-6 level was associated with inferior survival (hazard ratio, 6.1; P = .024). Our analysis shows that IL-6 and IL-10 levels contribute to the natural history of PEL. Inflammatory cytokines and tumor EBV status are the strongest prognostic factors. Pathogenesis-directed first-line regimens are needed to improve overall survival in PEL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lurain K, Polizzotto MN, Aleman K, et al. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood. 2019. PMID: 30782610. doi:10.1182/blood-2019-01-893339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。